Available datapackage for study 'A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids'
收藏DataCite Commons2026-03-03 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/dataPackages/PR00009881.0
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg
administered orally once daily for 12 weeks, compared with leuprorelin injection (once every
4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time) in patients with uterine fibroids.
提供机构：
Vivli
创建时间：
2026-03-03
